About Nizatidine API
Therapeutic Category Gastro-Intestinal - GI
CAS Number
76963-41-2
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, CEP Submitted, Japan DMF, Korea DMF
Mechanism of Action
Nizatidine competes with histamine for binding at the H2-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.
Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Rabeprazole Sodium (Form Y)
Gastro-Intestinal - GI
Vonoprazan Fumarate
Gastro-Intestinal - GI
Pantoprazole Sodium
Gastro-Intestinal - GI
Omeprazole Magnesium (Amorphous & Crystalline)
Gastro-Intestinal - GI
Omeprazole Base (Crystalline)
Gastro-Intestinal - GI
Nizatidine
Gastro-Intestinal - GI
Esomeprazole Magnesium Trihydrate
Gastro-Intestinal - GI
Famotidine
Gastro-Intestinal - GI
FAQs
Nizatidine belongs to a class of drugs known as H2 blockers.
-
Inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.
-
Duodenal & Gastric Ulcer, Erosive Esophagitis and Gastroesophageal Reflux Disease- 300 mg orally (150mg twice).
-
We offer Crystalline form (No specific Polymorphic Form is claimed).
-
XCEED Platform (or) write to us at [email protected].